Renal cell carcinoma, also called renal adenocarcinoma, is a most common type of kidney cancer. It accounts for 90% to 95% of malignant neoplasms arising from the kidney. The Global Renal Cell Carcinoma Drugs Market was around US$ 3.2 Billion in 2015, and is anticipated to reach to US$ 4.2 Billion by 2020. It is believed that, the market will continue the trend of its incessant growth owing to factors, such as rising geriatric population, increasing prevalence of renal cell carcinoma, quick diagnosis with modern imaging techniques, increasing risk from lifestyle related factors, and grants and tax credits. All these factors are luring more pharmaceutical companies to enter this market and develop drugs for this rare disease. The major drug in this market includes Sutent, Opdivo, Votrient, and Inyta amongst others.
The report, “Global Renal Cell Carcinoma Drugs Market 2020”, provides in depth analysis of the commercialized drugs for the treatment of RCC. The market has been segmented on the basis of geographic regions. The clinical pipeline of renal cell carcinoma drugs has also been provided. Various drivers and challenges have been listed down that affect the Global Renal Cell Carcinoma Drugs Industry. We have also deduced a list of top companies in this industry. These companies include Pfizer, Roche, Novartis, Bayer, and GlaxoSmithKline. The trends and developments in the industry and mergers for enhanced renal cell carcinoma drug manufacturing capability have been highlighted.
The report also covers the key players of the Global Renal Cell Carcinoma Drugs Market. The commercialized drugs of each company and their drugs in pipeline have also been highlighted. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of the players. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Renal Cell Carcinoma Drugs Market.
Some of the key findings of the report are:
– ADCs- A Novel Treatment Option for RCC
– Pfizer leads the RCC market
– North America is the largest market for RCC drugs